ReviewCurrent opinion in allergy and clinical immunology2014
Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways.
Review in Current opinion in allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.Genes · 2024Review
- Guidelines for mouse and human DC generation.European journal of immunology · 2023Article
- KIT as a master regulator of the mast cell lineage.The Journal of allergy and clinical immunology · 2022Review
- Review
- Review
- Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes.Scientific reports · 2020Article
- Lung Function in African American Children with Asthma Is Associated with Novel Regulatory Variants of the KIT LigandGenetics · 2020Article
- Cutting-edge genetics in obsessive-compulsive disorder.Faculty reviews · 2020Review
- Extracorporeal Shock Waves Increase Markers of Cellular Proliferation in Bronchial Epithelium and in Primary Bronchial Fibroblasts of COPD Patients.Canadian respiratory journal · 2020Article
- Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Oncotarget · 2017Review
- Cytochrome P450s in human immune cells regulate IL-22 and c-Kit via an AHR feedback loop.Scientific reports · 2017Article
- Pathways of impending disease flare in African-American systemic lupus erythematosus patients.Journal of autoimmunity · 2017Article
- Immunological off-target effects of imatinib.Nature reviews. Clinical oncology · 2016Review
- Stem Cell Factor (SCF) is a putative biomarker of antidepressant response.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Article
- A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs.BioMed research international · 2016Review
- Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.Oncotarget · 2015Article
- Intratumoral CD3+ T-lymphocytes immunoexpression and its association with c-Kit, angiogenesis, and overall survival in malignant canine mammary tumors.Analytical cellular pathology (Amsterdam) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewBinding of the receptor tyrosine kinase, c-kit, to its ligand, stem cell factor (SCF), mediates numerous biological functions. Important roles for c-kit in hematopoiesis, melanogenesis, erythropoiesis, spermatogenesis, and carcinogenesis are well documented. Similarly, activation of mast cells and eosinophils by c-kit ligation has long been known to result in degranulation with concomitant release of pro-inflammatory mediators including cytokines. This review will highlight a recently discovered function of c-kit in regulating the adaptive immune responses with relevance to allergic diseases. RECENT
findingsRecent studies in a number of laboratories including our own highlight the previously unappreciated functions for c-kit in immunological processes. Increased expression of c-kit and its ligand, SCF, on dendritic cells by Th2/Th17-inducing stimuli leads to c-kit activation and immune skewing toward these subsets and away from Th1 responses. Treatment of dendritic cells with inhibitors of c-kit activation such as imatinib mesylate (Gleevec) induces breach of T-cell tolerance, skewing of responses toward Th1, and activation of natural killer cells. SUMMARY: Taken together, these observations suggest that the c-kit/SCF axis may be a useful target for redirecting deleterious immune responses in various disease settings, including allergic diseases that are often associated with Th2 and Th17 responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.